Seattle Genetics to Host Conference Call and Webcast Discussion of First Quarter 2019 Financial Results on April 25, 2019
April 04 2019 - 8:00AM
Business Wire
Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it
will report its first quarter 2019 financial results on Thursday,
April 25, 2019 after the close of financial markets. Following the
announcement, company management will host a conference call and
webcast discussion of the results and provide a general corporate
update. Access to the event can be obtained as follows:
LIVE access on Thursday, April 25, 2019
1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
- Telephone 877-260-1479 (domestic) or +1
334-323-0522 (international); conference ID 6169352
- Webcast with slides available at
www.seattlegenetics.com in the Investors section
REPLAY access
- Telephone replay will be available
beginning at approximately 4:30 p.m. PT on Thursday, April 25, 2019
through 5:00 p.m. PT on Monday, April 29, 2019 by calling
888-203-1112 (domestic) or +1 719-457-0820 (international);
conference ID 6169352
- Webcast replay will be available on the
Seattle Genetics website at www.seattlegenetics.com in the
Investors section
About Seattle Genetics
Seattle Genetics, Inc. is an emerging multi-product, global
biotechnology company that develops and commercializes
transformative therapies targeting cancer to make a meaningful
difference in people’s lives. ADCETRIS® (brentuximab vedotin)
utilizes the company’s industry-leading ADC technology and is
currently approved for the treatment of multiple CD30-expressing
lymphomas. Beyond ADCETRIS, the company has established a pipeline
of novel targeted therapies at various stages of clinical testing,
including three in ongoing pivotal trials for solid tumors.
Enfortumab vedotin for metastatic urothelial cancer and tisotumab
vedotin for metastatic cervical cancer utilize our proprietary ADC
technology. Tucatinib, a small molecule tyrosine kinase inhibitor,
is in a pivotal trial for HER2-positive metastatic breast cancer.
In addition, we are leveraging our expertise in empowered
antibodies to build a portfolio of proprietary immuno-oncology
agents in clinical trials targeting hematologic malignancies and
solid tumors. The company is headquartered in Bothell,
Washington, and has a European office in Switzerland. For more
information on our robust pipeline,
visit www.seattlegenetics.com and follow @SeattleGenetics
on Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190404005040/en/
InvestorsPeggy Pinkston(425)
527-4160ppinkston@seagen.com
MediaMonique Greer(425) 527-4641mgreer@seagen.com
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Seagen (NASDAQ:SGEN)
Historical Stock Chart
From May 2023 to May 2024